Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6664080 | 1.00 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL15425667 | 0.91 | ADORA2A (0.73) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL9791716 | 0.91 | ADORA2A (0.73) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL10240316 | 0.91 | ADORA2A (0.73) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL15426678 | 0.91 | ADORA2A (0.73) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL15426676 | 0.87 | ADORA1 (0.55) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL15425654 | 0.87 | ADORA1 (0.55) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL6660666 | 0.86 | ADORA3 (0.79) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL13454924 | 0.82 | PI4KA (0.62) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| SCHEMBL15426674 | 0.80 | ADORA2A (0.49) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030856-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6740644-B2 | ADENOSINE DERIVATIVES, AGONISTS AT THE ADENOSINE A1 RECEPTOR | SMITHKLINE BEECHAM CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20030158146-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | US | disclosed |
| US-6544960-B1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158146-A1 | Chemical compounds | CNR1, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885ADORA2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.